Skip to main content
Caplight Logo









MapLight Therapeutics

MapLight Therapeutics

Public
Burlington, MassachusettsBiotechhttps://maplightrx.com/

MapLight Therapeutics is now publicly traded

The data on this page reflects MapLight Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Oct 29, 2025

Last Round

Series D

Jul 28, 2025

Est. Valuation at Exit

$816M

Total Funding Raised

$945.4M

Company Overview

MapLight Therapeutics is a biopharmaceutical company that develops circuit-specific pharmacotherapies for central nervous system disorders using a proprietary platform combining optogenetics, transcriptomics, and spatial biology.

Sector

Biotech

AI Layer

Application

Keywords

biotechnologyCNS disordersdrug discoveryclinical trialsschizophrenia treatmentbiotech stockAI drug discoveryclinical-stage biotechbioinformaticsdrug pipelinemolecular simulationpharma pipelinein-silico drug discoverybiotech play

MapLight Therapeutics Comparables

Compare MapLight Therapeutics with similar companies based on industry and business-model similarity.

MapLight Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Neurosterix
74%
Tortugas Neuroscience
74%
Amani Therapeutics
71%

MapLight Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
IPOOct 29, 2025
Series DJul 28, 2025
Series COct 30, 2023
GrantAug 4, 2021
Series BFeb 1, 2021
Grant
Nov 30, 2020

Key People

Founding team and executive leadership

Chris Kroeger

Chief Executive Officer

Executive Team

MapLight Therapeutics Investors

Notable investors and investment history

MapLight Therapeutics investors
InvestorRounds
JefferiesIPO
Avego ManagementSeries D
ForbionSeries D
Life Sciences at Goldman Sachs AlternativesSeries D
TD SecuritiesSeries C
Blue Owl CapitalSeries D, Series C, Series A, Series B
5AM VenturesSeries D, Series C, Series A, Series B, Seed

Recent news

Latest coverage and updates

  • receives_financingAug 13, 2026

    MapLight Therapeutics, Inc. received financing of $150M in private placement financing on Aug 13th '26.

  • is_developingAug 10, 2026

    MapLight Therapeutics, Inc. is developing muscarinic receptor agonist on Aug 10th '26.

  • identified_as_competitor_ofJul 27, 2026

    MapLight Therapeutics, Inc. was planning to identify as competitor of Bristol-Myers Squibb Co on Jul 27th '26.

MapLight Therapeutics Filings

Explore SEC and related filing metadata, where available.

MapLight Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersBurlington, Massachusetts
Employee Range124
Year Founded2019
Last FundingJul 28, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?